Last reviewed · How we verify
Medical standard treatment
At a glance
| Generic name | Medical standard treatment |
|---|---|
| Also known as | Drugs |
| Sponsor | Universidad de Granada |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer (PHASE2)
- Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) (PHASE2)
- Bedside Bike Early Mobilization Program for Inpatients (NA)
- Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer (PHASE2)
- Ablation Versus Medical Management of Atrial Fibrillation in HFpEF (NA)
- Perioperative Telemonitoring to Optimize Cancer Care and Outcomes (NA)
- Exercise for the Treatment of Cancer-Related Sarcopenia (NA)
- Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Medical standard treatment CI brief — competitive landscape report
- Medical standard treatment updates RSS · CI watch RSS
- Universidad de Granada portfolio CI